Osteoporosis care

Yes. Men can develop osteoporosis and need an evaluation of fractures, bone density, medicines and other risk factors. Screening recommendations and treatment eligibility differ by age, sex and clinical history, so the clinician assesses the individual rather than applying one women’s screening rule to everyone.

Confirm the exact service at the selected clinic before booking. Evaluation, prescribing, testing, training and administration are separate capabilities. Confirm whether the clinic provides assessment, prescribing, DXA coordination or actual medication administration. Not every address establishes infusion capacity or stock. Visits, imaging, labs, medicine and administration may have separate coverage. Confirm the ordered product, next dose and clinician responsible for follow-up when moving care from another clinician.

The repeat DXA interval depends on the previous results, fracture risk, new risk factors and whether treatment is being monitored. Bring the full dated reports so the clinician can compare measured sites and decide when another scan would change care. It is not automatically repeated at every injection or annual visit.

DXA helps assess bone density, but fracture history and clinical risk also matter. Screening and repeat testing depend on age, risk and prior results. Steroid use, hormone changes, some chronic illnesses and nutritional problems can contribute to bone loss. A clinician reviews secondary causes and treatment options rather than using a DXA score alone.

Bring DXA dates and measurements, fracture and fall history, dental concerns, current medicines and recent kidney and calcium-related tests. Mention heart attack or stroke, pregnancy potential and planned dental procedures. Different products need different laboratory checks. Ask whether DXA or other tests are onsite or require a separate imaging appointment.

The 2025 USPSTF recommendation calls for screening women age 65 or older and postmenopausal women under 65 who have increased fracture risk after clinical risk assessment. Evidence is insufficient for a universal screening recommendation in men. Prior fragility fractures, secondary causes and bone-loss medicines need a clinical evaluation rather than this routine-screening rule.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. Bring prior DXA reports and fracture records. Discuss activity, fall prevention, calcium and vitamin D intake and whether medication is indicated. If injection or infusion treatment is selected, review the product’s eligibility and safety tests before administration. Plan how treatment continues, and what follows a limited course or discontinuation, before the first dose.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Bring DXA dates and measurements, fracture and fall history, dental concerns, current medicines and recent kidney and calcium-related tests. Mention heart attack or stroke, pregnancy potential and planned dental procedures. Different products need different laboratory checks. Ask whether DXA or other tests are onsite or require a separate imaging appointment.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Follow-up reviews fractures, falls, side effects, adherence and bone density at an individualized interval. Prolia or Jubbonti must not simply be interrupted without a replacement plan. Evenity is limited to 12 monthly doses and generally needs consideration of subsequent antiresorptive treatment. The clinician decides whether a bisphosphonate pause is suitable for an individual patient.